Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119538) titled 'Clinical study of Rezvilutamide and Adebrelimab combined with stereotactic body radiation therapy for metastatic castration-resistant prostate cancer' on Feb. 28.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The first affiliated hospital of anhui medical university
Condition:
Metastatic castration-resistant prostate cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-15
Target Sample Size: Trial Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=283906
Published by HT Digital C...